Prime Medicine (PRME) Stock Forecast, Price Target & Predictions

PRME Stock Forecast

Prime Medicine stock forecast is as follows: an average price target of $17.25 (represents a 494.83% upside from PRME’s last price of $2.90) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

PRME Price Target

The average price target for Prime Medicine (PRME) is $17.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $12.00. This represents a potential 494.83% upside from PRME's last price of $2.90.

PRME Analyst Ratings

Buy

According to 6 Wall Street analysts, Prime Medicine's rating consensus is 'Buy'. The analyst rating breakdown for PRME stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Prime Medicine Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 07, 2024	Maury Raycroft	Jefferies	$15.00	$5.40	177.78%	417.24%
Apr 02, 2024	David Nierengarten	Wedbush	$12.00	$6.32	89.87%	313.79%
Oct 09, 2023	Kostas Biliouris	BMO Capital	$19.00	$8.75	117.14%	555.17%
Nov 14, 2022		Morgan Stanley	$23.00	$21.12	8.90%	693.10%

The latest Prime Medicine stock forecast, released on May 07, 2024 by Maury Raycroft from Jefferies, set a price target of $15.00, which represents a 177.78% increase from the stock price at the time of the forecast ($5.40), and a 417.24% increase from PRME last price ($2.90).

Prime Medicine Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$13.50
Last Closing Price	$2.90	$2.90	$2.90
Upside/Downside	-100.00%	-100.00%	365.52%

In the current month, the average price target of Prime Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prime Medicine's last price of $2.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	BMO Capital	Outperform	Outperform	Hold
May 20, 2024	H.C. Wainwright		Buy	Initialise
May 15, 2024	Citigroup		Buy	Upgrade
Apr 08, 2024	Cowen & Co.		Buy	Initialise
Apr 03, 2024	Wedbush	Buy	Outperform	Initialise
Apr 02, 2024	Wedbush		Buy	Initialise
Nov 14, 2022	Morgan Stanley		Equal-Weight	Initialise

Prime Medicine's last stock rating was published by BMO Capital on Oct 01, 2024. The company gave PRME a "Outperform" rating, the same as its previous rate.

Prime Medicine Financial Forecast

Prime Medicine Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$109.40K	$117.56K	$126.33K	$135.75K	$50.00K	$3.79M	$3.79M	$3.79M	$8.94M	$7.09M	$1.63M	$1.92M	$5.71M	$1.67M
High Forecast	$109.40K	$117.56K	$126.33K	$135.75K	$50.00K	$3.79M	$3.79M	$3.79M	$8.94M	$7.09M	$1.63M	$1.92M	$5.71M	$1.67M
Low Forecast	$109.40K	$117.56K	$126.33K	$135.75K	$50.00K	$3.79M	$3.79M	$3.79M	$8.94M	$7.09M	$1.63M	$1.92M	$5.71M	$1.67M
# Analysts	3	3	4	5	4	5	2	7	10	1	1	3	6	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Prime Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRME's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Prime Medicine EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	3	3	4	5	4	5	2	7	10	1	1	3	6	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-51.46M
Avg Forecast	$83.79K	$90.04K	$96.75K	$103.97K	$38.29K	$2.90M	$2.90M	$2.90M	$6.85M	$5.43M	$1.25M	$1.47M	$4.38M	$1.28M
High Forecast	$83.79K	$90.04K	$96.75K	$103.97K	$38.29K	$2.90M	$2.90M	$2.90M	$6.85M	$5.43M	$1.25M	$1.47M	$4.38M	$1.28M
Low Forecast	$83.79K	$90.04K	$96.75K	$103.97K	$38.29K	$2.90M	$2.90M	$2.90M	$6.85M	$5.43M	$1.25M	$1.47M	$4.38M	$1.28M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-40.31%

undefined analysts predict PRME's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Prime Medicine's previous annual EBITDA (undefined) of $NaN.

Prime Medicine Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	3	3	4	5	4	5	2	7	10	1	1	3	6	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-50.71M
Avg Forecast	$-53.89M	$-52.70M	$-51.50M	$-50.30M	$-46.31M	$-43.46M	$-43.12M	$-41.92M	$-48.37M	$-46.15M	$-46.68M	$-54.48M	$-66.59M	$-52.00M
High Forecast	$-53.89M	$-52.70M	$-51.50M	$-50.30M	$-46.31M	$-43.46M	$-43.12M	$-30.27M	$-37.21M	$-46.15M	$-46.68M	$-54.48M	$-61.04M	$-52.00M
Low Forecast	$-53.89M	$-52.70M	$-51.50M	$-50.30M	$-46.31M	$-43.46M	$-43.12M	$-54.73M	$-58.29M	$-46.15M	$-46.68M	$-54.48M	$-73.52M	$-52.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.98%

Prime Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRME's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Prime Medicine SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	3	3	4	5	4	5	2	7	10	1	1	3	6	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$10.49M
Avg Forecast	$100.80K	$108.32K	$116.40K	$125.08K	$46.07K	$3.49M	$3.49M	$3.49M	$8.24M	$6.53M	$1.50M	$1.77M	$5.27M	$1.54M
High Forecast	$100.80K	$108.32K	$116.40K	$125.08K	$46.07K	$3.49M	$3.49M	$3.49M	$8.24M	$6.53M	$1.50M	$1.77M	$5.27M	$1.54M
Low Forecast	$100.80K	$108.32K	$116.40K	$125.08K	$46.07K	$3.49M	$3.49M	$3.49M	$8.24M	$6.53M	$1.50M	$1.77M	$5.26M	$1.54M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	6.83%

Prime Medicine's average Quarter SG&A projection for Dec 23 is $5.27M, based on 6 Wall Street analysts, with a range of $5.26M to $5.27M. The forecast indicates a -49.82% fall compared to PRME last annual SG&A of $10.49M (Sep 23).

Prime Medicine EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	3	3	4	5	4	5	2	7	10	1	1	3	6	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.55
Avg Forecast	$-0.45	$-0.44	$-0.43	$-0.42	$-0.39	$-0.36	$-0.36	$-0.35	$-0.40	$-0.39	$-0.39	$-0.45	$-0.56	$-0.43
High Forecast	$-0.45	$-0.44	$-0.43	$-0.42	$-0.39	$-0.36	$-0.36	$-0.25	$-0.31	$-0.39	$-0.39	$-0.45	$-0.51	$-0.43
Low Forecast	$-0.45	$-0.44	$-0.43	$-0.42	$-0.39	$-0.36	$-0.36	$-0.46	$-0.49	$-0.39	$-0.39	$-0.45	$-0.61	$-0.43
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.27%

According to undefined Wall Street analysts, Prime Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRME previous annual EPS of $NaN (undefined).

Prime Medicine Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EDIT	Editas Medicine	$1.21	$10.20	742.98%	Buy
PRME	Prime Medicine	$2.90	$17.25	494.83%	Buy
SANA	Sana Bio	$1.61	$8.00	396.89%	Buy
IPSC	Century Therapeutics	$1.04	$5.00	380.77%	Buy
RLAY	Relay Therapeutics	$4.36	$18.00	312.84%	Buy
NTLA	Intellia Therapeutics	$11.97	$44.00	267.59%	Buy
VERV	Verve Therapeutics	$6.02	$14.00	132.56%	Buy
BEAM	Beam Therapeutics	$26.59	$55.00	106.84%	Buy
RPRX	Royalty Pharma	$25.54	$51.00	99.69%	Buy
CRSP	CRISPR Therapeutics	$40.02	$77.50	93.65%	Buy
CRBU	Caribou Biosciences	$1.67	$3.00	79.64%	Buy
BPMC	Blueprint Medicines	$89.40	$122.60	37.14%	Buy
DNA	Ginkgo Bioworks	$9.66	$7.00	-27.54%	Buy

PRME Forecast FAQ

Is Prime Medicine a good buy?

Yes, according to 6 Wall Street analysts, Prime Medicine (PRME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of PRME's total ratings.

What is PRME's price target?

Prime Medicine (PRME) average price target is $17.25 with a range of $12 to $23, implying a 494.83% from its last price of $2.9. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Prime Medicine stock go up soon?

According to Wall Street analysts' prediction for PRME stock, the company can go up by 494.83% (from the last price of $2.9 to the average price target of $17.25), up by 693.10% based on the highest stock price target, and up by 313.79% based on the lowest stock price target.

Can Prime Medicine stock reach $4?

PRME's average twelve months analyst stock price target of $17.25 supports the claim that Prime Medicine can reach $4 in the near future.

What are Prime Medicine's analysts' financial forecasts?

Prime Medicine's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.43M (high $11.43M, low $11.43M), average EBITDA is $8.75M (high $8.75M, low $8.75M), average net income is $-175M (high $-163M, low $-188M), average SG&A $10.53M (high $10.53M, low $10.53M), and average EPS is $-1.46 (high $-1.362, low $-1.566). PRME's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $489.04K (high $489.04K, low $489.04K), average EBITDA is $374.54K (high $374.54K, low $374.54K), average net income is $-208M (high $-208M, low $-208M), average SG&A $450.59K (high $450.59K, low $450.59K), and average EPS is $-1.74 (high $-1.74, low $-1.74).